Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00136058|
Recruitment Status : Completed
First Posted : August 26, 2005
Last Update Posted : December 16, 2011
|Condition or disease||Intervention/treatment||Phase|
|Osteoporosis||Procedure: bone densitometry (DEXA) Drug: alendronate or risedronate||Phase 3|
All hip fracture patients in the Edmonton area will be screened for eligibility (mini-mental status >20, not on active osteoporosis pharmacologic therapy). All patients will have informed consent obtained. Patients will be randomized to 2 groups:
- Group 1: Active intervention. The fracture manager will arrange for bone densitometry (DEXA) to be done 3-6 months after the fracture. If the patient meets standard criteria for osteoporosis, therapy with a bisphosphonate (alendronate or risedronate) will be instituted by the study physicians.
- Group 2: Usual care. Patients will receive basic information about calcium and vitamin D and osteoporosis and told to follow up with their family doctor. At 6 months, patients will be contacted to determine if they have had a BMD done or started on active (drug) osteoporosis therapy. If not, the fracture manager will arrange the BMD and if appropriate therapy will be started by the study physicians.
All patients will be followed for 1 year. The primary endpoints are the number of patients who get a BMD and the number who are started on active osteoporosis therapy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|
|Study Start Date :||January 2002|
|Study Completion Date :||April 2006|
- the number of patients who get a BMD and the number who are started on active osteoporosis therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136058
|University of Alberta|
|Edmonton, Alberta, Canada, T6G2S2|
|Principal Investigator:||Donald W Morrish, MD, PhD||University of Alberta|